Fate Therapeutics, Inc. (FATE)
| Market Cap | 145.33M +37.2% |
| Revenue (ttm) | 6.65M -51.2% |
| Net Income | -136.32M |
| EPS | -1.15 |
| Shares Out | 116.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 743,084 |
| Open | 1.220 |
| Previous Close | 1.240 |
| Day's Range | 1.220 - 1.280 |
| 52-Week Range | 0.910 - 1.940 |
| Beta | 2.14 |
| Analysts | Buy |
| Price Target | 4.10 (+228.0%) |
| Earnings Date | May 14, 2026 |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum... [Read more]
Financial Performance
In 2025, Fate Therapeutics's revenue was $6.65 million, a decrease of -51.24% compared to the previous year's $13.63 million. Losses were -$136.32 million, -26.82% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for FATE stock is "Buy." The 12-month stock price target is $4.1, which is an increase of 228.00% from the latest price.
News
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent ...
Fate Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Presenters highlighted the scalability and accessibility of iPSC-derived CAR T-cell therapies, with FT819 showing strong safety and efficacy in SLE and lupus nephritis. Next-generation products aim to expand into solid tumors and complex autoimmune diseases, with key data updates expected at EULAR and ACR.
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...
Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2026
FT819, an off-the-shelf CAR T-cell therapy, is advancing in lupus nephritis with strong early efficacy and safety data, outpatient administration, and scalable manufacturing. A pivotal phase II trial is planned for the second half of the year, while next-generation multiplex-edited products are in development for broader autoimmune indications.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and ...
Fate Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
iPSC-derived therapies enable scalable, off-the-shelf cell products with strong safety and efficacy in lupus and a growing pipeline for autoimmune and oncology indications. Manufacturing and patient access are improving, with pivotal studies and new programs advancing toward 2026.
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate...
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive ...
Fate Therapeutics Transcript: Cantor Global Healthcare Conference 2025
FT819, an off-the-shelf CD19 CAR T-cell, is showing strong efficacy and safety in autoimmune trials, with rapid site activation and plans for pivotal studies next year. Manufacturing and regulatory progress support a robust pipeline, with next-gen solid tumor products advancing.
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free defini...
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-...
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) Oral presenta...
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications Updated clin...
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process
Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2025
Leadership is focusing resources on advancing FT819 in autoimmune diseases, with strong early safety and efficacy data and a streamlined clinical strategy. Financial discipline and non-dilutive funding are extending runway, while innovation continues in next-gen CAR T and NK cell platforms.
Fate Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference
Off-the-shelf cell therapy platform shows resilience to supply chain and regulatory risks, with strong early SLE trial results and a focus on expanding into autoimmune indications. Favorable safety, cost, and outpatient potential drive increased clinical interest.
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE
Fate Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference
The presentation highlighted advances in iPSC-derived, off-the-shelf living drugs, emphasizing scalable, cost-effective manufacturing and strong safety in clinical programs. FT819 showed promising results in SLE, and next-generation CAR-Ts like FT825 target solid tumors with multi-antigen strategies.
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s...
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile